Literature DB >> 23456422

A consensus envelope protein domain III can induce neutralizing antibody responses against serotype 2 of dengue virus in non-human primates.

Hsin-Wei Chen1, Shih-Jen Liu, Yi-Shiuan Li, Hsueh-Hung Liu, Jy-Ping Tsai, Chen-Yi Chiang, Mei-Yu Chen, Chyi-Sing Hwang, Chin-Cheng Huang, Hui-Mei Hu, Han-Hsuan Chung, Sze-Hsien Wu, Pele Chong, Chih-Hsiang Leng, Chien-Hsiung Pan.   

Abstract

We have previously demonstrated that vaccination with a subunit dengue vaccine containing a consensus envelope domain III with aluminum phosphate elicits neutralizing antibodies against all four serotypes of dengue virus in mice. In this study, we evaluated the immunogenicity of the subunit dengue vaccine in non-human primates. After vaccination, monkeys that received the subunit vaccine with aluminum phosphate developed a significantly strong and long-lasting antibody response. A specific T cell response with cytokine production was also induced, and this correlated with the antibody response. Additionally, neutralizing antibodies against serotype 2 were detected in two of three monkeys. The increase in serotype-2-specific antibody titers and avidity observed in these two monkeys suggested that a serotype-2-biased antibody response occurs. These data provide evidence that a protective neutralizing antibody response was successfully elicited in non-human primates by the dengue subunit vaccine with aluminum phosphate adjuvant.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23456422     DOI: 10.1007/s00705-013-1639-1

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  19 in total

1.  Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates.

Authors:  Sean P McBurney; Justine E Sunshine; Sarah Gabriel; Jeremy P Huynh; William F Sutton; Deborah H Fuller; Nancy L Haigwood; William B Messer
Journal:  Vaccine       Date:  2016-04-13       Impact factor: 3.641

2.  DENV-2 subunit proteins fused to CR2 receptor-binding domain (P28)-induces specific and neutralizing antibodies to the Dengue virus in mice.

Authors:  Jazmín García-Machorro; Moisés López-González; Olivia Barrios-Rojas; Cynthia Fernández-Pomares; Claudia Sandoval-Montes; Leopoldo Santos-Argumedo; Nicolás Villegas-Sepúlveda; Benito Gutiérrez-Castañeda; Leticia Cedillo-Barrón
Journal:  Hum Vaccin Immunother       Date:  2013-07-23       Impact factor: 3.452

3.  The Immunodominance Change and Protection of CD4+ T-Cell Responses Elicited by an Envelope Protein Domain III-Based Tetravalent Dengue Vaccine in Mice.

Authors:  Hsin-Wei Chen; Hui-Mei Hu; Szu-Hsien Wu; Chen-Yi Chiang; Yu-Ju Hsiao; Chia-Kai Wu; Chun-Hsiang Hsieh; Han-Hsuan Chung; Pele Chong; Chih-Hsiang Leng; Chien-Hsiung Pan
Journal:  PLoS One       Date:  2015-12-29       Impact factor: 3.240

4.  Enhanced performance of an innovative dengue IgG/IgM rapid diagnostic test using an anti-dengue EDI monoclonal antibody and dengue virus antigen.

Authors:  Jihoo Lee; Young-Eun Kim; Hak-Yong Kim; Mangalam Sinniah; Chom-Kyu Chong; Hyun-Ok Song
Journal:  Sci Rep       Date:  2015-12-11       Impact factor: 4.379

5.  Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice.

Authors:  Chen-Yi Chiang; Chien-Hsiung Pan; Mei-Yu Chen; Chun-Hsiang Hsieh; Jy-Ping Tsai; Hsueh-Hung Liu; Shih-Jen Liu; Pele Chong; Chih-Hsiang Leng; Hsin-Wei Chen
Journal:  Sci Rep       Date:  2016-07-29       Impact factor: 4.379

Review 6.  Recent advances in understanding dengue.

Authors:  Sophie Yacoub; Juthathip Mongkolsapaya; Gavin Screaton
Journal:  F1000Res       Date:  2016-01-19

Review 7.  Current progress in dengue vaccines.

Authors:  Shu-Wen Wan; Chiou-Feng Lin; Shuying Wang; Yu-Hung Chen; Trai-Ming Yeh; Hsiao-Sheng Liu; Robert Anderson; Yee-Shin Lin
Journal:  J Biomed Sci       Date:  2013-06-13       Impact factor: 8.410

8.  Induction of neutralizing antibodies against four serotypes of dengue viruses by MixBiEDIII, a tetravalent dengue vaccine.

Authors:  Hui Zhao; Tao Jiang; Xi-Zhen Zhou; Yong-Qiang Deng; Xiao-Feng Li; Shui-Ping Chen; Shun-Ya Zhu; Xi Zhou; E-De Qin; Cheng-Feng Qin
Journal:  PLoS One       Date:  2014-01-21       Impact factor: 3.240

9.  Long-term immunogenicity studies of formalin-inactivated enterovirus 71 whole-virion vaccine in macaques.

Authors:  Chia-Chyi Liu; Chyi-Sing Hwang; Wun-Syue Yang; Dan-Chin Tsai; Sze-Hsien Wu; Ai-Hsiang Chou; Yen-Hung Chow; Suh-Chin Wu; Jen-Ren Wang; Jen-Ron Chiang; Chin-Cheng Huang; Chien-Hsiung Pan; Pele Chong
Journal:  PLoS One       Date:  2014-09-08       Impact factor: 3.240

Review 10.  Utility, limitations, and future of non-human primates for dengue research and vaccine development.

Authors:  Carlos A Sariol; Laura J White
Journal:  Front Immunol       Date:  2014-09-24       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.